Loading
companiesCompany
Il-Yang Pharmaceutical
Il-Yang Pharmaceutical is a South Korea-based pharmaceutical company that leads 2 cancer trials in OnCo, testing the BCR-ABL inhibitor radotinib (Supect) in chronic myeloid leukaemia.
Also called: Il-Yang PharmIlyang일양약품
Overview
Il-Yang Pharmaceutical is a South Korean pharmaceutical manufacturer founded in 1946 that produces prescription and over-the-counter medicines, influenza vaccines and health products. Its in-house new drugs include Noltec (ilaprazole) and Supect (radotinib), a BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukaemia. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo (2 in phase 3 or 2/3): NCT03459534 (phase 3, A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failur...) and NCT03722420 (phase 3, Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Yongin, KR
Scorecard
All companies#105of 1244 companies, score 50
- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 1 in phase 3, 0 earlier, 1 targets, 536 registry studies. Formula on the scorecards page.
Type
Large pharma · KRX:007570
Stage
Public
Website
Founded
1946
ApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)
Imatinib · Gleevec
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
Phase 3Oral kinase inhibitor
Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.
Similar pages
- PersonTimothy P. Hughes
Shares Chronic myeloid leukaemia (CML), Imatinib.
- CancerChronic myeloid leukaemia, chronic phase
Shares Radotinib, A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs, Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China), Chronic myeloid leukaemia (CML).
- TrialDASISION
Shares Chronic myeloid leukaemia (CML), Imatinib.
- PersonBud Romine
Shares Chronic myeloid leukaemia (CML), Imatinib.
- TrialA Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Shares Chronic myeloid leukaemia (CML), Imatinib.
- Key paperFirst imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia
Shares Chronic myeloid leukaemia (CML), Imatinib.
- PersonJanet Rowley
Shares Chronic myeloid leukaemia (CML), Imatinib.
- TermSokal and ELTS risk scores (chronic myeloid leukaemia)
Shares Chronic myeloid leukaemia (CML), Imatinib.